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determine infarct size and IMH. In 23 Yorkshire swine, the circumﬂex
coronary artery was occluded for 75 minutes by a balloon catheter.
rADAMTS13 or vehicle was administered intracoronary following
reperfusion. Myocardial injury and infarct characteristics were
assessed using cardiac enzymes, ECG, and histopathology.
RESULTS In patients with IMH, VWF activity and VWF antigen were
signiﬁcantly elevated directly after PCI and for all subsequent mea-
surements, and ADAMTS13 activity signiﬁcantly decreased at 4 and 7
days following PCI; in comparison to patients without IMH. VWF ac-
tivity and ADAMTS13 activity were not related to infarct size. For
rADAMTS13 treated animals no differences in myocardial infarct size,
IMH, or formation of microthrombi were witnessed in comparison to
controls.
CONCLUSIONS No correlation was witnessed between VWF/
ADAMTS13 and infarct size in patients; and intracoronary adminis-
tration of rADAMTS13 did not decrease infarct size or IMH in a porcine
model of myocardial ischemia-reperfusion. These data dispute the
imbalance in ADAMTS13 and VWF as the cause of no reﬂow. Restoring
the imbalance between ADAMTS13 and VWF most likely will not be
beneﬁcial in STEMI patients already treated with standard antiplatelet
and anticoagulant therapy.
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BACKGROUND Randomized clinical trials evaluating the role of
thrombus aspiration (TA) in patients undergoing primary percuta-
neous coronary intervention (PPCI) for ST-segment elevation
myocardial infarction (STEMI) have yielded contrasting results.
Therefore, the efﬁcacy and safety of TA in STEMI is unclear.
METHODS We included study-level data from 25 randomized
controlled trials (RCTs), involving 21,733 patients with STEMI and
PPCI. The primary efﬁcacy endpoint was MACE according to study
deﬁnitions; the primary safety endpoint was stroke. We sought to
evaluate the efﬁcacy and safety of TA during PPCI for STEMI
compared with conventional PPCI alone.
RESULTS The mean weighted follow-up time across studies was 8.2
months. Compared with conventional PPCI, TA was associated with
signiﬁcant lower risk for MACE (Relative Risk [RR]: 0.91; 95% Conﬁ-
dence Interval [CI]: 0.83 – 1.00; p ¼ 0.042). However, this beneﬁt in
MACE was counterbalanced by a signiﬁcant increase in the risk for
stroke (RR: 1.58; 95% CI: 1.11 – 2.25; p ¼ 0.011). There were no differ-
ences in the risk of myocardial infarction (RR: 0.94; 95% CI: 0.78 – 1.12;p ¼ 0.486), target vessel revascularization (RR: 0.93; 95% CI: 0.82 –
1.04; p ¼ 0.2) and deﬁnite or probable stent thrombosis (RR: 0.84; 95%
CI: 0.66 – 1.07; p ¼ 0.148). TA was associated with an ostensible lower
risk for all-cause mortality, which did not reach statistical signiﬁcance
(RR: 0.88; 95% CI: 0.78 – 1.00; p ¼ 0.059).
CONCLUSIONS Compared with conventional PPCI for STEMI,
adjunctive TA reduces the risk of subsequent MACE. However, the
beneﬁt in MACE is counterbalanced by an increased risk in stroke.
Considering the above potential risks and beneﬁts, TA should be
considered in selected patients lesions rather than routinely.
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BACKGROUND Prior studies have found that smokers with ST-
segment elevation myocardial infarction (STEMI) have lower rates of
mortality and adverse events. This phenomenon has been called “the
smoker’s paradox.” We sought to investigate the impact of smoking
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tients with large anterior STEMI undergoing primary percutaneous
coronary intervention.
METHODS Participants from the INFUSE-AMI trial were categorized
according to smoking status at clinical presentation (current or prior
smoking vs. no history of smoking). The primary imaging endpoint
was cardiac magnetic resonance (MRI) assessed IS (% of left ven-
tricular mass) at 30 days. The secondary MRI endpoint was the
percentage of microvascular obstruction (MVO) of total myocardial
mass at 5 days and the total stunning and remodeling index (SRI) at
30 days. SRI was classiﬁed as worse (-1), absence of (0), mild (þ1)
and marked left ventricular function recovery ( þ2). The second-
ary endpoint was the rate of MACE at 1 year, deﬁned as the com-
posite of death, reinfarction, new-onset heart failure, or re-
hospitalization.
RESULTS Out of 447 patients enrolled in the INFUSE-AMI trial, 271
(60.6%) were current or past smokers, of whom 206 (76%) were
current smokers at the time of clinical presentation. Compared with
nonsmokers, smokers were younger and had a lower prevalence of
clinical comorbidities. At 30 days, there was no difference in me-
dian IS between smokers and nonsmokers (16.8% vs. 17.4%;
p¼0.67). However, smokers had lower median MVO of total
myocardial mass at 5 days (0.1% vs. 1.5%; p¼0.04) and higher 30-
day mean stunning and remodeling index (1.83.2 vs. 0.92.1;
p¼0.03). At 1 year, smokers had lower rates of MACE (4.5% vs.
9.7%; p¼0.03). After multivariable adjustment for baseline con-
founders, smoking status had no effect on 30-day IS (standard er-
ror: 1.04; p¼0.42) or 1-year MACE (adjusted hazard ratio: 0.74; 95%
conﬁdence interval: 0.39–1.41; p¼0.36).
CONCLUSIONS In the INFUSE-AMI trial, smoking status had no effect
on MRI IS at 30 days compared with patients without a history of
smoking. Smokers exhibited lower total myocardial mass MVO and
better left ventricular recovery. Finally, while smokers had lower 1-
year MACE rates in the unadjusted analysis, this association was lost
following adjustment for baseline confounders.
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BACKGROUND Large randomized trials have failed to show a bene-
ﬁcial effect of statin treatment in chronic heart failure (HF). The in-
vestigators tried to evaluate the long-term effects of statin therapy in
patients with new onset HF following acute myocardial infarction
(AMI).
METHODS Between 2008 and 2011, we studied 1,055 patients with
AMI who had newly developed severe acute HF [left ventricular
ejection fraction  40%] and were discharged alive. The patients were
divided into two groups, a statin group (n ¼ 756) and a no-statin group
(n ¼ 299). We investigated the one-year major adverse cardiovascular
events (MACEs) and survival rate of each group. We then performed a
propensity-score matched analysis.
RESULTS In the original cohort, one-year MACEs (all-cause mortality,
MI, and any revascularization) were similar between the two groups
(16.5% vs. 14.7% in the statin or no-statin groups; p ¼ 0.47). Pro-
pensity-score matching yielded 256 pairs, and in that population we
observed comparable results in terms of MACEs (18.0% vs. 12.5% in
the statin or no-statin groups, p ¼ 0.11) and mortality (5.1% vs. 3.5% in
the statin or no-statin groups, p ¼ 0.51) (Table). Cox-regression anal-
ysis revealed that statin therapy was not an independent predictor for
occurrence of a MACE [Hazard ratio (HR) 1.11, 95% CI 0.79-1.57, p ¼
0.54] or all-cause mortality (HR 1.42, 95% CI 0.75-2.70, p ¼ 0.28)





(n[256)Overall MACE* 44 (14.7%) 125 (16.5%) 0.47 32 (12.5%) 46 (18.0%) 0.11All-cause mortality 12 (4.0%) 43 (5.7%) 0.27 9 (3.5%) 13 (5.1%) 0.51Cardiac death 9 (3.0%) 32 (4.2%) 0.35 6 (2.3%) 9 (3.5%) 0.60Non-cardiac death 3 (1.0%) 11 (1.5%) 0.56 3 (1.2%) 4 (1.6%) 0.99Myocardial infarction 6 (2.0%) 16 (2.1%) 0.91 6 (2.3%) 5 (2.0%) 0.99Repeated
Revascularization24 (8.0%) 55 (7.3%) 0.68 17 (6.6%) 23 (9.0%) 0.41TLR 12 (4.0%) 28 (3.7%) 0.81 10 (3.9%) 13 (5.1%) 0.67TVR 4 (1.3%) 8 (1.1%) 0.70 4 (1.6%) 2 (0.8%) 0.69CABG 2 (0.7%) 6 (0.8%) 0.83 1 (0.4%) 0 (0%) 0.99Stent thrombosis 1 (0.3%) 7 (0.9%) 0.32 1 (0.4%) 5 (2%) 0.22*Composed of all-cause mortality, myocardial infarction and repeated revascularization.
CABG, coronary artery bypass grafting; CI, conﬁdence interval; HR, hazard ratio; MACE, major adverse
cardiovascular event; TLR, target-lesion revascularization; TVR, target-vessel revascularizationCONCLUSIONS Statin therapy did not reduce the long-term occur-
rence of MACEs or mortality in survivors of AMI with severe acute HF.
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BACKGROUND The recently published Trial of Routine Aspiration
Thrombectomy with PCI versus PCI Alone in Patients with STEMI
(TOTAL) has refuted the salutary effect of aspiration thrombectomy
(AT) in primary percutaneous coronary intervention (PPCI) for pa-
tients with ST-elevation myocardial infarction (STEMI). We sought to
perform an updated meta-analysis to assess clinical outcomes with AT
prior to PPCI compared with conventional PPCI alone due to the
availability of additional trial data.
METHODS All clinical trials (n¼20) that randomized patients
(n¼20,868) with STEMI between AT (n¼10,458) and PPCI (n¼10,410)
were included in this study.
